Total Quality
Score
If You Had Traded on This Analysis…
Pending
UNH
Long Entry
271.8400
2025-08-13
19:45 UTC
Target
434.1300
Fail
200.0000
Risk/Reward
1 : 2
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
Live PnL
—
P/L: —
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
The analysis compares Novo Nordisk (NOVOb) and UnitedHealth (UNH), both near 52-week lows. Revenue growth, profit margins, and returns on invested capital were analyzed. For Novo Nordisk the intrinsic value is estimated around $127.47 with the current price at $49.87. United Health's intrinsic value is estimated at $434, significantly above its market price of $252.37. Revenue growth is expected to be better for NOVO than UNH, operating margin is 47.7% and improving for NOVO, and WACC is 8.14%. However, Novo faces competition from Eli Lilly and compounded medications. UNH faces customer loss due to pricing and market exits, their OC to WACC ratio is below 1.